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Abstract
Background: The prognosis of prostate cancer patients with lymph node metastases so small they can only be
visualized by new imaging techniques as MR lymphography (MRL) is unknown. The purpose of this study was to
investigate the prognosis of prostate cancer patients with non-enlarged metastatic lymph nodes on MRL and to
identify a subgroup of MRL-positive patients who might be candidates for curative treatment.
Methods: The charts of 138 prostate cancer patients without enlarged lymph nodes on CT, in whom a pre-treatment
MRL was performed were reviewed. Endpoints were distant metastases-free survival and overall survival. Relation
between the following factors and outcome were investigated: T-stage, PSA value at diagnosis, Gleason score,
diameter (short axis and long axis) of the largest MRL-positive lymph node, number of MRL-positive lymph nodes, the
presence of extra-pelvic nodal disease, and the extent of resection of the positive lymph nodes. Kaplan-Meier analysis
was performed to estimate the survival functions.
Results: Of the 138 patients, 24 (17%) had a positive MRL. Patients with a short axis of the largest positive lymph node
of ≤8 mm had a significantly better 5-year distant metastases-free (79% vs 16%) and overall survival (81% vs 36%) than
patients with larger positive lymph nodes. This also accounted for patients with a largest long axis of ≤10 mm (71% vs
20% and 73% vs 40%, respectively). Outcome was also better in patients in whom all positive lymph nodes had been
resected.
Conclusion: A selection of MRL-positive patients with a good prognosis could be identified, consisting of patients with
small positive lymph nodes. In these patients, cure might be pursued.
Keywords: Prostate cancer, Lymphotrophic superparamagnetic nanoparticles, Magnetic resonance imaging, Lymph
node metastases, Radiotherapy
Background
Lymph node metastases in prostate cancer patients can
only be detected with conventional imaging methods as
computed tomography (CT) or magnetic resonance
imaging (MRI) when nodal enlargement exists, which
does not occur until late in the disease process [1].
Nodal involvement is therefore generally detected
through a lymph node dissection. Patients with nodal
involvement are historically considered to be incurable
[2]. However, several studies have shown that their
prognosis is highly variable [3,4]. Patients with a low
nodal metastastic tumor burden have a favorable out-
come after prostatectomy and lymph node dissection.
They can remain disease-free for many years [2].
The development of new imaging methods, such as
MR lymphography (MRL), has created the opportunity
to detect lymph node metastases at an early stage, in
non-enlarged lymph nodes [5]. MRL is a technique that
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uses the contrast agent ferumoxtran-10 to enhance MRI.
This method has a sensitivity of 80-100% and a specifi-
city of 87-99% for the detection of involved lymph nodes
in prostate cancer [6,7].
Patients in whom lymph node metastases are diagnosed
non-invasively at an early stage, before enlargement of the
lymph node occurs, form a new category, with an un-
known prognosis. Their outcome might be comparable to
that of patients with clinically occult metastases detected
by pelvic lymph node dissection.
With this new category of node-positive patients, a
treatment dilemma has arisen. Should we pursue cure
with surgery or locoregional radiotherapy, and if yes,
how should we select those patients that are most likely
to benefit? To address this issue, it is necessary to obtain
more data are about the course of the disease in these
patients.
The purpose of the present study was to investigate the
prognosis of CT-negative patients with positive lymph
nodes on MRL and to identify a subgroup of MRL positive
patients with a good prognosis, who might be candidates
for curative treatment.
Methods
Patient selection
Between January 2003 and May 2005, 150 patients with a
histopathologically proven intermediate to high-risk pros-
tate cancer (serum prostate-specific antigen level >10 ng/
mL, Gleason score >6, or T3 clinical stage), with lymph
nodes with a maximum diameter of 1.5 cm on CT, under-
went an MRL prior to local treatment in our institute in
the context of a pathological validation study. In all
patients, histopathological evidence was obtained, either
by pelvic lymph node dissection that was in some cases
extended based on MRL, or by CT-guided lymph node
biopsy. Twelve patients were excluded for the analysis as
follow-up data were not available or incomplete. The
charts of the remaining 138 patients were reviewed.
The study was approved by the Institutional Review
Board: Commissie Mensgebonden Onderzoek regio
Arnhem-Nijmegen and written informed consent was
obtained from all patients.
MRL scanning procedure
MRI images were obtained on a 1.5 T system (Sonata/
Symphony, Siemens, Erlangen, Germany; Gyroscan/Intera,
Philips, Eindhoven, Netherlands; or Horizon, GE Medical
Systems, Milwaukee, WI, USA) with pelvic phased array
coils. To suppress bowel peristalsis, Buscopan i.m. and i.v.,
and Glucagon i.m. were administered before scanning.
Patients were placed in the supine position with a knee
fix. Images were acquired from the entire pelvis and abdo-
men. Heesakkers et al. previously described the scanning
protocol in detail [6].
Twenty-four to 36 hours before MRI, Ferumoxtran-10
(Sinerem®, Guerbet, Paris, France) was injected intra-
venously. This contrast medium contains ultrasmall
superparamagnetic particles of iron oxide. These parti-
cles extravasate, and are transported to the lymph nodes
by macrophages. Iron particles give a low signal intensity
on a T2*-weighted MRI image. Metastases in the lymph
nodes block accumulation of the iron particles. The sig-
nal intensity of pathological nodes will therefore remain
high on a T2*-weighted MRI image, while the signal
intensity of normal lymph nodes becomes low [6,8].
Lymph nodes were considered malignant when they
completely or partially showed high signal intensity on a
T2*-weighted image [6]. All MRL images were analyzed
by an experienced radiologist.
Treatment and follow-up after MRL
After MRL, patients were treated for their disease,
according to the result of the histopathological exami-
nation. MRL patients that were histopathologically node-
negative were locally treated with prostatectomy or local
radiotherapy, patients that were node-positive received hor-
monal treatment. Two node-positive patients did undergo
a prostatectomy, because lymph node dissection and pros-
tatectomy were combined in one procedure after MRL was
negative. Follow-up took place every 3–6 months, for a
minimum of 5 years. At every visit, a PSA value was deter-
mined. A CT, MRI or bone scan was performed at the
physician’s discretion. In case of a recurrence patients were
treated depending on the site of recurrence.
Endpoints and statistical analysis
For statistical testing SPSS 16.0.01 (SPSS Inc. 1989–
2007) was used and a p < 0.05 was a priori deemed
significant.
Endpoints of the present study, that were determined
for patients with and without lymph node involvement on
MRL, were: distant metastases-free survival (DMFS) and
overall survival (OS). For DMFS, deaths were censored.
Survival rates were estimated with the Kaplan-Meier
method, and the unstratified log-rank statistical analysis
was used to test for differences.
Patients with a positive MRL
For patients with a positive MRL, the prognostic value of
tumor-related factors was investigated using Kaplan-Meier
analysis: T-stage, Gleason score (<7, 7 or >7), PSA
(≤10 ng/ml, >10 ng/ml).
Next, MRL-related factors were investigated: number
of positive lymph nodes, largest diameter of the largest
lymph node (mm), short axis diameter of the largest
lymph node (mm).
For these factors, ROC analysis was performed to
determine their predictive potential and to find the
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threshold with the highest accuracy. This threshold was
used to dichotomize the patients for Kaplan-Meier
analysis.
Further, the prognostic value of the presence or
absence of positive lymph nodes outside the pelvis was
determined. Positive lymph nodes above the L5/S1 inter-
space were considered to be outside the pelvis.
Last, it was investigated whether patients in whom all
MRL-positive lymph nodes had been removed had a bet-
ter prognosis compared to patients in whom only part of
the MRL-positive lymph nodes had been removed. To
determine whether all MRL-positive lymph nodes had
been removed, a comparison between the surgical re-
port, the pathology report, and the MRL result was
made.
Multivariate analysis could not be performed, due to
the relatively small number of MRL-positive patients.
Results
Total study population
The characteristics of the 138 patients are shown in
Table 1. Twenty-four patients had a positive MRL (17%).
Figure 1 shows an example of an MRL-positive and an
MRL-negative lymph node. In 2 patients with a
negative MRL, lymph node involvement was found
at histopathological verification. In 10 patients with
a positive MRL, histopathological examination was
negative.
Median follow-up time for all patients was 73 months
(range 4–101 months). Figure 2 shows the Kaplan-Meier
survival curves for DMFS (A) and OS (B) for patients
with a positive and for patients with a negative MRL.
Five-year DMFS was 94% for the MRL negative group,
and 49% for the MRL positive group. Five-year OS was
96% and 57% respectively.
Patients with a positive MRL
The Kaplan-Meier survival curves for both DMFS and
OS did not differ significantly between patients with a
PSA ≤10 ng/ml and >10 ng/ml, different clinical T-
stages, or different Gleason scores (<7, 7 or >7).
In ROC analysis, the number of positive lymph nodes
was not predictive for either endpoint. The short axis of
the largest positive lymph node was predictive for the
occurrence of distant metastases (area under the curve
(AUC) 0.76 with p = 0.03). The threshold at which the
highest accuracy (75%) was reached was 8 mm. The
short and the long axis of the largest lymph node were
both predictive of OS (AUC 0.82 with p = 0.01; AUC
0.74 with p = 0.05 respectively). Thresholds with the
best accuracy were 8 mm for the short axis and 10 mm
for the long axis diameter of the largest lymph node
(accuracy 84% and 76% respectively).
Based on these thresholds, patients were dichotomized.
Of the group with a short axis of the largest lymph node
of ≤8 mm, only 1 patient had a long axis of the largest
lymph node of >10 mm. Vice versa, of the patients with a
long axis of the largest lymph node of ≤10 mm, also only
1 patient had a lymph node with short axis of >8 mm.
Figure 3 shows the corresponding survival curves.
DMFS and OS were significantly better for patients in
whom the short axis of the largest positive lymph node
was ≤8 mm. Five-year DMFS was 79% versus 16% for
the group with a longer short axis. Five-year OS was
81% and 36%, respectively. Similar results were obtained
after dichotomization by the long axis size. Five-year
DMFS was 71% and 20% respectively, 5-year OS 73%
and 40% respectively.
There were 7 patients with extra-pelvic nodal disease.
Their distant metastases-free and overall survival did
not significantly differ from those of patients with nodal
disease limited to the pelvis.
In eight patients all MRL positive lymph nodes had been
removed. These patients had a significantly better 5-year
DMFS (80%) than patients in whom only part of the posi-
tive lymph nodes had been removed (35%; p = 0.04). OS
did not differ between the groups.
Table 1 Patient characteristics
Median
(range)
PSA 15.9
(2.8-260.0)
N (%)
Clinical
T-stage
1 31 (22%)
2 85 (62%)
3 22 (16%)
Gleason
score
Unknown 1 (1%)
5 4 (3%)
6 32 (23%)
7 62 (45%)
8 26 (19%)
9 10 (7%)
10 3 (2%)
MRL Result Negative 114 (83%)
Positive 24 (17%)
Result PA Negative 122 (88%)
Positive 16 (12%)
Therapy Prostatectomy 77 (56%)
Radiotherapy with neo-adjuvant hormonal
treatment
47 (34%)
Hormonal therapy 14 (10%)
Abbreviations: MRL magnetic resonance lymphography, PA pathology.
Meijer et al. Radiation Oncology 2013, 8:190 Page 3 of 7
http://www.ro-journal.com/content/8/1/190
Discussion
The presence of lymph node metastases in prostate cancer
is a poor prognostic sign [2], and patients with lymph
node metastases generally are considered incurable [2,4].
The present study shows that patients with a negative
MRL indeed have a far better outcome than MRL-positive
patients. However, within the group of MRL-positive
patients, a subgroup could be defined with a better prog-
nosis, consisting of patients with only small nodal metas-
tases. In these patients cure might be pursued, for
example by locoregional radiotherapy or resection of the
positive nodes.
CT and MRI have a very low sensitivity for the detec-
tion of lymph node metastases in prostate cancer [9].
The presence of lymph node metastases is therefore usu-
ally detected at pelvic lymph node dissection. However,
the development of more accurate imaging methods has
created the opportunity to detect lymph node involve-
ment at an early stage, in a non-invasive manner. MRL
is a very accurate imaging method, with a sensitivity of
85-100%, which can detect lymph node metastases even
in non-enlarged lymph nodes [6,7].
Thus a new category of patients emerges, whose prog-
nosis and the treatment from which they benefit require
further investigation. The present study aimed to take
the first steps in describing this group of patients.
MRL-positive patients had a significantly worse prog-
nosis compared to MRL-negative patients. Five-year OS
was 57%, which is comparable to the survival of lymph
node positive patients treated with androgen suppression
therapy alone in other reports [10]. However, patients
with small MRL positive lymph nodes (a short axis of
the largest positive lymph node of ≤8 mm or a long axis
of ≤10 mm), had a 5-year DMFS and OS of more than
70%. This was despite the fact that these patients were
treated palliatively. This is comparable to the prognosis
of high-risk node-negative patients treated with radio-
therapy [11,12]. Patients in whom all positive lymph
nodes had been removed had the best prognosis.
These findings reinforce the results from previous
studies investigating outcome after prostatectomy and
lymph node dissection. These retrospective studies have
shown that patients with limited lymph node involve-
ment have a far better outcome compared to patients
with more extensive lymph node involvement [2,4]. The
number of positive lymph nodes [3,4] and the size of the
largest positive lymph node [2] were prognostic factors.
Disease-specific survival was 99% at 5 years for patients
Figure 1 Example of a negative (A) and a positive (B) MRL. Upper panel: T1 image, which provides good visualization of non-enlarged lymph
nodes (arrows). Lower panel: T2* image. The positive lymph node (B) has a high signal intensity, because accumulation of the iron particles has
been blocked. This in contrast to the low signal intensity of the negative lymph node (A). Modified from: Hanneke J.M. Meijer et al.; Magnetic
resonance lymphography findings in patients with a biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. Int.
J. Radiat. Oncol. Biol. Phys. 2012; 84(5): 1186–1191.
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with a single lymph node metastasis [4], 84% at 15 years
for patients with up to 2 positive lymph nodes [3], and over
80% at 5 years for patients in whom the largest positive
lymph node was ≤ 10 mm. Five-year recurrence-free sur-
vival of the latter group was around 40% [2].
Although patients with limited lymph node involvement
seem to have a better outcome compared to patients with
more extensive nodal disease, the question remains: can
they be cured? The answer may be ‘yes’ for at least part of
the MRL-positive patients. The finding of the present
study that DMFS is high for patients with limited nodal
involvement, indicate a window of opportunity for cure
with locoregional treatment, before distant metastases
develop. This was also found by Leibel et al., who de-
scribed the outcome in patients with nodal disease treated
with pelvic lymphadenectomy and brachytherapy [13]. N1
(single lymph node metastasis <2 cm) patients had a bet-
ter DMFS than N2 (multiple lymph node metastases or
single lymph node metastasis >2 cm but <5 cm) patients.
This is further supported by the results of the above men-
tioned studies [2-4]. Our finding that patients in whom all
MRL-positive lymph nodes had been removed at pelvic
lymph node dissection had a very high 5-year DMFS of
80%, further substantiate this. This is also in line with the
findings of several retrospective studies indicating that the
larger the extent of a lymph node dissection, and thus the
higher the chance of removal of all nodal disease, the bet-
ter the prognosis [14,15].
Preferably, only lymph node positive patients without dis-
tant micrometastases would be selected for locoregional
treatment. The findings of the present study that patients
with small MRL-positive lymph nodes less often and less
early develop clinically apparent distant metastases, can
guide MRL-based patient selection for a potentially curative
locoregional treatment. When selecting node positive pa-
tients for locoregional treatment with MRL, the size of the
short axis of the largest lymph node should be the main se-
lection criterion, as there was significant overlap between
the group with a short axis of the largest MRL-positive
lymph node of ≤8 mm and the group with a long axis of
≤10 mm, with the short axis being a stronger prognostic
factor at ROC analysis.
MRL can yield important progress in locoregional treat-
ment for node positive patients. First, geographical miss of
positive lymph nodes can be reduced. Studies using the
sentinel node procedure or MRL to map the pattern of
lymph drainage in prostate cancer patients, have shown
that this is a larger problem than was previously thought.
Positive lymph nodes and sentinel nodes were found out-
side the area of routine lymph node dissection [16], as well
as outside the standard target volume for elective pelvis
irradiation in more than half of the patients [17,18]. The
possibility to target pathological lymph nodes more accu-
rate, will increase the effectiveness of locoregional treat-
ment in these patients.
Further, for radiotherapy, the use of MRL gives the
opportunity to boost the positive lymph nodes. This has
shown to be theoretically feasible, using an intensity modu-
lated radiotherapy technique [19]. Dose escalation to the
prostate has shown to improve outcome [20], and this may
also account for the involved lymph nodes.
Figure 2 Survival curves for MRL negative vs MRL positive
patients. A. Distant metastases-free survival. B. Overall survival.
p-value indicates level of statistical significance as determined with
unstratified log-rank statistical analysis Max =maximum.
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A limitation of the present study is the small number of
MRL-positive patients. The findings of this study should
therefore be interpreted as a first step towards identification
of MRL-positive patients with a good prognosis in whom
cure might be feasible.
A second limitation is that histopathological examination
was negative in 10 of 24 MRL- positive patients. In 4 of
these patients, however, the tissue sampling was not repre-
sentative, because the MRL-positive lymph nodes were not
removed, as was shown by a repeated MRL within 3 months
after the initial MRL. We elected to include all MRL-
positive patients for analysis. This because the aim of the
present study was to find prognostic factors based on MRL
without subsequent histopathological confirmation. This
might have influenced our results, certainly as the histo-
pathologically negative patients received a different
(curative) treatment. As the group was too small for
multivariate analysis, the influence of this factor on out-
come relative to that of the prognostic factors found in
our study could unfortunately not be investigated.
Conclusions
Whereas lymph node involvement on MRL was a poor
prognostic factor, a subgroup of MRL-positive patients
with a relatively good prognosis could be identified. Pa-
tients with a short axis of the largest lymph node ≤8 mm
or a long axis ≤10 mm had a good outcome, comparable
to that of high-risk node-negative prostate cancer patients.
These seem to be the patients in whom cure might be
pursued. Patients in whom all MRL-positive lymph nodes
had been resected, had a better prognosis than patients in
whom part of the nodal disease was left in situ. This
encourages the application of a locoregional curative treat-
ment in these patients.
Figure 3 Survival curves for subgroups of the MRL positive patients with different MRL related factors. Upper panel: Patients with a short
axis of the largest lymph node of ≤8 mm vs patients with a short axis of the largest lymph node of >8 mm. A. Distant metastases-free
survival. B. Overall survival. Lower panel: Patients with a long axis of the largest lymph node of ≤10 mm vs patients with a long axis of the
largest lymph node of >10 mm. C. Distant metastases-free survival. D. Overall survival. p-value indicates level of statistical significance as
determined with unstratified log-rank statistical analysis Max = maximum.
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